实用临床医药杂志2011，Vol.15Issue(17)：105-106,118,3.
重组人血管内皮抑制素联合化疗治疗晚期胃癌临床观察
Clinical observation of recombinant human endostatin combined with chemotherapy for advanced gastric cancer
王芳 1阿依夏木 1柳江1
作者信息
- 1. 新疆自治区人民医院肿瘤内科,新疆乌鲁木齐,830001
- 折叠
摘要
Abstract
Objective To study the efficacy and safety of recombinant human endostatin (Oxaliplatin + Gio capsules) combined treatment in advanced gastric cancer. Methods Twenty-one cases of second - line retreatment of advanced gastric cancer patients received recombinant hu man endostatin combined with chemotherapy drugs. The efficacy and toxicity after chemotherapy were evaluated. Results All 21 patients completed a total of 86 treatment cycles, among which, there was 1 case of CR, 8 cases of PR, 7 cases of SD, and 5 cases of PD. PR was 42. 9%, and QOL improvement rate was 76.2 %. Main side effects included bone marrow suppression and gas trointestinal reactions and there were no significant cardiovascular toxicity and bleeding. Conclusion Recombinant human endostatin combined with chemotherapy for advanced gastric cancer patients has a good effect. It does not increase the toxicity of chemotherapy and it is well tolerated. There fore it is worthy of clinical application.关键词
胃癌/重组人血管内皮抑制素/化疗/联合治疗Key words
gastric cancer/ recombinant human endostatin/ chemotherapy/ combination therapy分类
医药卫生引用本文复制引用
王芳,阿依夏木,柳江..重组人血管内皮抑制素联合化疗治疗晚期胃癌临床观察[J].实用临床医药杂志,2011,15(17):105-106,118,3.
